Funded Health Care Startups in Atlanta
Rounds in this Atlanta health care set span 2020-11-22 (StartBox) through 2025-08-01 (Higher Powers), with the most recent two years clustering heavily in…
Rounds in this Atlanta health care set span 2020-11-22 (StartBox) through 2025-08-01 (Higher Powers), with the most recent two years clustering heavily in 2024: 14 of the 26 entries have round dates in 2024, including multiple disclosures between 2024-10-09 and 2024-10-25 (Inhibikase Therapeutics at $110M on 2024-10-09; OncoLens at $16M on 2024-10-24; YoungHeartValve at $3M on 2024-10-25). The disclosed amounts show a clear size outlier: Inhibikase Therapeutics’ $110M (2024-10-09) is the only disclosed round above $50M and dwarfs the next-largest disclosed amount of $45M (Azalea Health on 2022-12-15). Stage disclosure is also skewed toward non-transparent labeling: 12 of 26 entries are marked “Series Unknown,” and 3 of 26 are “undisclosed,” leaving fewer explicit stage calls. Overall, the list is exclusively Atlanta, Georgia, and the health care category is consistent across all 26 rows.
Most recent rounds
26 shownRelated listings
Frequently asked
What’s the largest disclosed round in these Atlanta health care entries, and how does it compare to other disclosed amounts?
Inhibikase Therapeutics reported a disclosed $110M on 2024-10-09, the only disclosed round above $50M. The next-largest disclosed amount is $45M from Azalea Health on 2022-12-15, making the $110M round a clear outlier relative to the rest of the disclosed figures (e.g., $30M Menda Health on 2024-10-16; $23M OXOS Medical on 2023-04-05).
How concentrated are the round dates—do they cluster in a narrow recent window?
Yes. The 26-row set concentrates in 2024, with 14 entries dated in 2024. It also shows a tight late-October 2024 cluster across multiple companies, including Inhibikase Therapeutics ($110M) on 2024-10-09, OncoLens ($16M) on 2024-10-24, and YoungHeartValve ($3M) on 2024-10-25.
Are there repeated gaps in disclosure—how often are rounds labeled “Series Unknown” or “undisclosed”?
Stage and amount labeling is frequently non-specific: 12 of 26 entries use “Series Unknown,” and 3 of 26 entries are “undisclosed” for amount. Examples include CHOICES (2024-10-10) as “Series Unknown” with an “undisclosed” amount, and Patientory (2024-07-02) listed as “Series Unknown” with an “undisclosed” amount.
Which stages appear often enough to suggest a pattern despite the ‘Series Unknown’ labels?
Explicit stages repeat less than the unknowns, but Seed shows up multiple times: The Contract Network (Seed, 2023-08-02 at $8M), Syntax Health (Seed, 2023-06-08 at $8M), and PURSUANT HEALTH and others are “Series Unknown” rather than Seed. Visible non-Seed labels include Series A for OXOS Medical ($23M on 2023-04-05) and Series B for OncoLens ($16M on 2024-10-24).
Which entries are most recent in this list, and do they include large disclosed rounds?
The most recent date shown is 2025-08-01 (Higher Powers) at $300K under an Angel round. In late 2024, however, multiple large disclosed rounds appear close together: Inhibikase Therapeutics ($110M) on 2024-10-09 and OncoLens ($16M) on 2024-10-24, indicating large financings near the top of the timeline rather than only smaller checks.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.